Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ: INCY )

70.42 +0.41 (+0.59%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc... 
Via Benzinga
Incyte's Pemazyre Wins Conditional Approval For Bile Duct Cancer In Canada
Health Canada has given conditional approval to Incyte Corporation's (NASDAQ: INCY) Pemazyre (pemigatinib) to treat cholangiocarcinoma. Cholangiocarcinoma... 
Via Benzinga
The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight
Biotech stocks declined for the week ending Sept. 17, extending the losses from the previous week. European Society for Medical Oncology presentations, vaccine news, clinical... 
Via Benzinga
Exposures Product Safety
Price Over Earnings Overview: Incyte
In the current market session, Incyte Inc. (NASDAQ:INCY) is trading at $72.46, after a 0.1% gain. However, over the past month, the stock fell by 4.23%, and in the... 
Via Benzinga
Incyte Announces Ruxolitinib Cream Data Accepted for Presentation at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress
From Incyte
Via Business Wire
FDA Hits JAK inhibitors With Heart Safety, Cancer Warnings: All You Need To Know
The FDA wrapped up its long-awaited review of Pfizer Inc's (NYSE: PFE) large, randomized trial evaluating the safety of JAK inhibitors Xeljanz and Xeljanz XR... 
Via Benzinga
Exposures Product Safety
AbbVie Stock: Why A New FDA Order Hit It Harder Than Rivals Pfizer, Lilly
AbbVie stock collapsed Wednesday after the FDA said it would have to add a warning to the label for arthritis drug Rinvoq. 
Via Investor's Business Daily
Exposures Product Safety
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
Incyte - MorphoSys's Diffuse Large B-Cell Lymphoma Drug Wins European Approval
The European Commission (EC) has granted conditional approval to Incyte Corporation (NASDAQ: INCY) - MorphoSys AG's (NASDAQ: MOR) Minjuvi (... 
Via Benzinga
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)... 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
From Incyte
Via Business Wire
For Hedge Funds, This Is The Worst 6 Months Since The Financial Crisis: Here's Why
The most popular hedge fund positions have fared exceptionally poorly in recent months. The core issues behind recent (and continuing) hedge fund underperformance: concentration, crowding and... 
Via Talk Markets
Week In Review: Sino Biological Stages $772 Million IPO On ChiNext Exchange
Sino Biological​​​, a Beijing company that offers biological research reagents to global markets, completed a $772 million IPO on Shenzhen's ChiNext Exchange. On the first day of trading, the stock... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
BriaCell, ImaginAb Join Forces To Assess Imaging Tech In Breast Cancer Trial
BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced a multi-year, non-exclusive license agreement with ImaginAb Inc for developing next-generation... 
Via Benzinga
Incyte to Present at Upcoming Investor Conference
From Incyte
Via Business Wire
Incyte Out Licenses Lymphoma Drug To InnoCare In Greater China
Incyte Corporation (NASDAQ: INCY) and InnoCare have entered into a collaboration and license agreement to develop and commercial tafasitamab in Greater... 
Via Benzinga
Incyte and InnoCare Announce Collaboration and License Agreement for Tafasitamab in Greater China
From Incyte
Via Business Wire
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies
Photo by Chokniti Khongchum from Pexels In 2020, there were 2.3 million women globally diagnosed with breast cancer and 685,000 deaths, according to the World Health Organization... 
Via Benzinga
Topics Death
Exposures Death
Is the PD-(L)1 Party Over After Incyte's FDA Rejection?
There's definitely already a crowded market for PD-1 and PD-L1 immunotherapies. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 10) Alnylam Pharmaceuticals,... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Tuesday
Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the biggest company by market cap to set a new 52-week low.... 
Via Benzinga
Incyte Corporation (INCY) Q2 2021 Earnings Call Transcript
INCY earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9) Adagio Therapeutics, Inc. (... 
Via Benzinga
Exposures COVID-19
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
From Incyte
Via Business Wire
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant... 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates
The month of July was disappointing from the perspective of Food and Drug Administration decisions, as the agency handed down mostly negative verdi... 
Via Benzinga
A Preview Of Incyte's Earnings
Incyte (NASDAQ:INCY) will be releasing its next round of earnings this Tuesday, August 03. For all of the relevant information, here is your guide for Tuesday's Q2 earnings... 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.